 SAN FRANCISCO and SAN DIEGO, March 19, 2021 GLOBE NEWSWIRE -- Kinnate Biopharma Inc. Nasdaq: KNTE Kinnate, a biopharmaceutical company focused on the discovery and development of small molecule kinase inhibitors for difficult-to-treat, genomically defined cancers, today announced that it will be added to the Russell 2000 Index as part of the planned first quarter IPO additions scheduled to join the Russell US Indexes after US equity markets close on March 19, 2021. 